MAHA leaders praise Europe's food rules — but skip its sugar taxes, food labels, and health care. Can selective emulation fix U.S. chronic disease?

July 10, 2025 Check out STAT+

Sponsored By

Alex Hogan/STAT MAHA's European food envy is full of contradictions MAHA leaders praise Europe's food rules — but skip its sugar taxes, food labels, and health care. Can selective emulation fix U.S. chronic disease? By Sarah Todd STAT+ | FDA publishes rejection letters sent to drugmakers, with a big caveat FDA's Marty Makary says release of rejection letters will help drugmakers and investors understand decisions behind denials. But there's a big caveat. By Andrew Joseph and Lizzy Lawrence FDA grants full approval to Moderna's Covid vaccine for children but limits eligibility The shot, called Spikevax, is cleared for kids who have at least one condition putting them at increased risk. By Helen Branswell Adobe STAT+ | How Regeneron, maker of a best-selling eye drug, is using patent tactics to try to thwart competition The battle over Eylea has focused interest on a pair of congressional bills that attempt to address how drug companies exploit the U.S. patent system. By Ed Silverman STAT+ | Renasant Bio, an underdog in the race to develop kidney disease therapies, raises $54.5 million The company plans to develop two therapies for a common renal condition called autosomal dominant polycystic kidney disease, or ADPKD. By Allison DeAngelis STAT+ | Opinion: How to evaluate GLP-1s and Medicare costs? Here's one idea CMS should create a new value-based care payment pilot that would test coverage of GLP-1s on beneficiaries. By Soumi Saha and Somaieh McMullan NIH grant cuts, FDA transparency questions, and biotech M&A In this week's episode, a closer look at the NIH's grant-cutting legal playbook and a not-so-transparent transparency push by the FDA chief. By Adam Feuerstein, Allison DeAngelis, and Elaine Chen STAT+ | Eyes on Soleno's Prader-Willi drug launch In this week's edition of "Adam's Biotech Scorecard," Adam also hears a a Cogent-Blueprint analysis that favors the bears. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser